Shenzhen Kangtai Biological Products (300601.SZ): Application for clinical trial of adsorbed acellular pertussis (components) combined vaccine (for adults, teenagers, and children) has been accepted.
Kangtai Biological (300601.SZ) announced that its wholly-owned subsidiary, Beijing Minhai Biological Technology Co., Ltd. (Minhai Biological), received a acceptance notification from the National Medical Products Administration today, approving the clinical trial application for the research and development of a combined adsorbed acellular pertussis (component) vaccine for adults, adolescents, and children.
Shenzhen Kangtai Biological Products (300601.SZ) announced that its wholly-owned subsidiary, Beijing Minhai Biological Technology Co., Ltd. (referred to as "Minhai Biological"), received a notice of acceptance issued by the National Medical Products Administration today, allowing the acceptance of Minhai Biological's clinical trial application for the research and development of an adsorbed acellular pertussis (component) combined vaccine (for adults, adolescents, and children).
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
